Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer.
Wonkyo ShinHye-Joo LeeSeong J YangE Sun PaikHyun-Jin ChoiTae-Joong KimChel Hun ChoiJeong-Won LeeDuk-Soo BaeByoung Gie KimPublished in: Obstetrics & gynecology science (2018)
The ETI combination regimen shows comparatively low toxicity and modest activity in heavily pretreated recurrent or persistent EOC patients with more than 6 months of PFI after last platinum treatment.